Tag Archives: SABCS
SABCS 2020: The Breast Cancer-to-Addiction Pipeline and What to Do About It
By Jayla Burton, Program Officer
Each year at the San Antonio Breast Cancer Symposium (SABCS), the Breast Cancer Action team assesses the latest treatment research so folx can make the best-informed decisions about their care. This often includes calling out the harms... Read more
Posted in Articles
SABCS 2020: Why More Tests Won’t Solve the Breast Cancer Epidemic and Other Takeaways
By Karuna Jaggar, Former Executive Director and SABCS Guest Writer
In our “take action,” “more is better,” “gotta do something” culture, most people assume that more medial testing will lead to better treatments. After all, many assume, the more we know about a... Read more
Posted in Articles
SABCS 2020
By Jayla Burton, Program Officer
For decades billions of dollars have been poured into breast cancer research. And each December clinicians and researchers from around the world gather at the San Antonio Breast Cancer Symposium (SABCS) to share the latest study results. For... Read more
SABCS 2020: Patient-centered language and our for-profit healthcare system
By Tibby Reas Hinderlie, Communications Officer
The San Antonio Breast Cancer Symposium (SABCS) is the world’s largest annual breast cancer conference, and the stated intended audience is “an international audience of academic and private physicians and... Read more
Posted in Articles
SABCS 2020: Immunotherapy Part 4 – Sacituzumab Govitecan Improves Overall Survival for Metastatic Triple Negative Breast Cancer
By Karuna Jaggar, Former Executive Director and SABCS Guest Writer
In April 2020, the FDA approved a new type of immunotherapy, the antibody drug conjugate sacituzumab govitecan (brand name Trodelvy), a name so unpronounceable that even doctors at SABCS struggled and generally... Read more
Posted in Articles
SABCS 2020: Immunotherapy Part 3 – Atezolizumab Does Not Worsen Patient Reported Quality of Life for Early Stage Triple Negative Breast Cancer
By Karuna Jaggar, Former Executive Director and SABCS Guest Writer
Atezolizumab (brand name Tencentriq) was the first immunotherapy approved for breast cancer, just over a year and a half ago, as noted in my first immunotherapy blog post, for metastatic triple negative breast... Read more
Posted in Articles
SABCS 2020: Immunotherapy Part 2 – Pembrolizumab Can Be Paired With Any Partner Chemo
By Karuna Jaggar, Former Executive Director and SABCS Guest Writer
As explained in the prior blog post, immunotherapy seeks to harness the immune system to recognize and target cancer cells. The immunotherapy drug pembrolizumab (brand name Keytruda) is a checkpoint inhibitor... Read more
Posted in Articles
SABCS 2020: The Hallmarks of Cancer and the Hope of Immunotherapy
By Karuna Jaggar, Former Executive Director and SABCS Guest Writer
Cancer is a complex disease that includes breakdowns in multiple biological systems that allow tumors to grow. Understanding these mechanisms, sometimes referred to as the “Hallmarks of Cancer,” gives... Read more
Posted in Articles
SABCS 2020: Helping Patients by Doing Less: No Chemo Needed for Even More Breast Cancers
By Karuna Jaggar, Former Executive Director and SABCS Guest Writer
Good news for many postmenopausal women with early stage, hormone positive breast cancer. Two new studies presented at the 2020 the San Antonio Breast Cancer Symposium (SABCS) confirm that the majority of these... Read more
Posted in Articles
SABCS 2020: Life—and Birth!—after Breast Cancer
By Karuna Jaggar, Former Executive Director and SABCS Guest Writer
For people who want to have a biological child after breast cancer, there are a number of questions and concerns. Dr. Eva Blondeaux provided largely reassuring data about pregnancy in a paper presented on... Read more
Posted in Articles
a project of Breast Cancer Action